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Description:  
Matrix metalloproteinase 12 (MMP12) is one of the twenty-three members of the peptidase M10 
family which are responsible for the breakdown of the extracellular matrix3. MMP12 is a well-
studied protease that degrades elastin 1. In the lungs of smokers, MMP12 digests elastin which 
acts as a chemokine to recruit a pro-inflammatory immune response. Additionally, MMP12 is a 
well-studied mediator of arterial stiffening in both acute and chronic settings through the 
degradation of elastin 2. This finding makes MMP12 a major therapeutic target in wound healing 
and scar formation following myocardial infarction. Previous studies have examined ways to 
selectively inhibit MMP12 to modulate the pro-inflammatory response. An ongoing challenge in 
creating a clinically useful inhibitor is selectivity. MMP proteins share similar structures and 
functions therefore, most inhibitors of MMP12 also inhibit other MMP proteins. This has 
prevented the development of new treatments based on MMP although the evidence does support 
this as a tool with untapped potential. The protein data bank has an MMP12 protein complexed 
with the inhibitor called EEG under the code 3LIK3.  EEG fits into the S1 loop of the protein 
without disturbing the conformation of the loop conformation. Murine trials were found with 
corresponding data for another MMP12 inhibitor known as AS111793 which was shown to 
reduce inflammation associated with cigarette smoke. A series of inhibitors were created using 
key components of EEG and AS111793. It was found that the hybrid compound created had a 
higher binding affinity than AS111793, but less affinity than EEG. This may be because a 
majority of the solvents and elements were removed from the inhibitor which did not allow the 
docking to occur. The initial goal was to make an inhibitor that has structures that enable it to 
stick better inside the S1 loop to improve selectivity 3. We plan to build on this work and modify 
EEG to create a new inhibitor and test its binding using Py-Rx modeling software.  
 
Specific Model Details: The original paper studied four different models based on four MMP 12 
inhibitors. The PDB being used in this research project is 3LIK. It was chosen because it 
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